Arformoterol Tartrate Inhalation Solution
Product Images NDC 73289-0072

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate Inhalation Solution (NDC 73289-0072). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aucta Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Molecule (Bro01 0036 01)

Molecule (Bro01 0036 01)
FDA Label Image

Ifu-fig-1 (Bro01 0036 05)

Ifu-fig-1 (Bro01 0036 05)
FDA Label Image

Ifu-fig-2 (Bro01 0036 06)

Ifu-fig-2 (Bro01 0036 06)
FDA Label Image

Ifu-fig-3 (Bro01 0036 07)

Ifu-fig-3 (Bro01 0036 07)
FDA Label Image

Ifu-fig-4 (Bro01 0036 08)

Ifu-fig-4 (Bro01 0036 08)
FDA Label Image

Ifu-fig-5 (Bro01 0036 09)

Ifu-fig-5 (Bro01 0036 09)
FDA Label Image

Ifu-fig-6 (Bro01 0036 10)

Ifu-fig-6 (Bro01 0036 10)
FDA Label Image

Carton-30ct (Carton 30ct)

Carton-30ct (Carton 30ct)
FDA Label Image

Carton-60ct (Carton 60ct)

Carton-60ct (Carton 60ct)
FDA Label Image

Foil-card (Foilcard)

Foil-card (Foilcard)
FDA Label Image

Foil-single (Foilsingle)

Foil-single (Foilsingle)
This is a description of Arformoterol Tartrate Inhalation Solution. It is recommended to open the foil pouch just prior to administration. The solution contains 15 micrograms of arformoterol per 2 L of solution. It is advised to protect from light and excessive heat. The product can be stored at room temperature for up to 6 weeks. The code date and lot number are provided for product identification.*
FDA Label Image

Trial-fig (Trial Fig)

Trial-fig (Trial Fig)
This text provides data on the mean change in FEV over time for Clinical Trial A, comparing a placebo group with a group using a 15 mcg arformoterol tartrate inhalation solution BID. The measurements are taken at Week 0 (Day 1) and Week 12, showing baseline FEV values for each group. The chart displays the mean change in FEV at various hours postdose for both groups. The information can be used to evaluate the efficacy of the medication in improving FEV in patients with respiratory conditions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.